RxDoctor Payments Data

Lee Coleman, MD

Ophthalmology · Greenwood, MSNPI 1336147271

Payments from drug & device makers

$2,619in general payments, 2019–2025

Across 113 payments — averaging $23.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • AbbVie$316
  • Aerie Pharmaceuticals, Inc.$119
  • Bausch & Lomb Americas Inc.$118
  • Sight Sciences, Inc.$105
  • Sun Pharmaceutical Industries Inc.$90
  • plus $583 from 14 others

What the payments were for

  • Food & beverage$2,619100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,619 in reported general payments places this provider in the 55th percentile of 150 ophthalmology providers in Mississippi.

See all ophthalmology providers in Mississippi

Medicare billing

Part B allowed, 2024
$503,850
Medicare patients
1,417
Services billed
4,795

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CombiganBrimonidine Tartrate/Timolol144$60,515
LumiganBimatoprost62$29,395
Prednisolone Acetate497$25,189
VyzultaLatanoprostene Bunod30$16,962
Ketorolac Tromethamine410$13,311
MoxifloxacinMoxifloxacin Hcl415$10,947
Latanoprost1,508$9,970
RestasisCyclosporine16$8,275
Alphagan PBrimonidine Tartrate15$6,156
Timolol Maleate288$3,329
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat183$2,812
SimbrinzaBrinzolamide/Brimonidine Tart13$2,639
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol20$2,600
Travoprost23$2,083
Brimonidine Tartrate158$1,818

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCombigan, Lumigan, Restasis, Alphagan P$316$104,341237 claims
Bausch & Lomb Americas Inc.Vyzulta$118$16,96230 claims
AlconSimbrinza$1,289$2,63913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 150 ophthalmology providers in Mississippi.

Other ophthalmology in Greenwood

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →